Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Emerging subspecialties in neurology: neuroimmunology.
Acceptance of pain in neurological disorders: Associations with functioning and psychosocial well-being.
Effect of interferon beta-1a on B7.1 and B7.2 B-cell expression and its impact on T-cell proliferation.
Lipopolysaccharide-induced blood-brain barrier disruption: roles of cyclooxygenase, oxidative stress, neuroinflammation, and elements of the neurovascular unit.
Evidence of extensive RNA oxidation in normal appearing cortex of multiple sclerosis brain.
Management of fatigue in persons with multiple sclerosis.
Heparin-induced thrombocytopenia following plasma exchange in patients with demyelinating neurological disease.
Psychiatric comorbidity in multiple sclerosis: It's not the genes.
Is There A Pulse Wave Encephalopathy Component To Multiple Sclerosis?
Blood cells and endothelial barrier function.
Fibroblast growth factor signalling in multiple sclerosis: inhibition of myelination and induction of pro-inflammatory environment by FGF9.
Association of Postural Sway with Disability Status and Cerebellar Dysfunction in People with Multiple Sclerosis: A Preliminary Study.
GM-CSF: An immune modulatory cytokine that can suppress autoimmunity.
Two assessments to evaluate imagery ability: translation, test-retest reliability and concurrent validity of the German KVIQ and Imaprax.
Abstracts of the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. October 10-13, 2012. Lyon, France.
Demyelinating disease: NMO spectrum disorders: clinical or molecular classification?
Targeting ion channels for the treatment of autoimmune neuroinflammation.
[Interferons and autoimmune diseases].
Apparent Diffusion Coefficient Histograms in the Follow-up of Relapsing-Remitting Multiple Sclerosis.
Interactions of environment and genes in multiple sclerosis.
FTY720 inhibits tumor growth and enhances the tumor-suppressive effect of topotecan in neuroblastoma by interfering with the sphingolipid signaling pathway.
Monitoring technology for wheelchair users with advanced multiple sclerosis.
Trial and error in clinical studies: lessons from ATAMS.
Inhibition of hydroxymethylglutaryl-coenzyme a reductase reduces Th1 development and promotes Th2 development.
IL-23 Plasma level measurement in relapsing remitting multiple sclerosis (RRMS) patients compared to healthy subjects.

Pages